Fenwick & West represented KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, in its underwritten public offering of 4,600,000 shares, which included the exercise in full by the underwriters of their over-allotment option to purchase 600,000 additional shares of common stock, at a price to the public of $17.00 per share.

Jefferies LLC, Stifel, Nicolaus & Company, Inc. and Cantor Fitzgerald & Co. acted as joint book-running managers for the offering. Roth Capital Partners acted as co-manager.

The Fenwick transaction team included corporate lawyers Rob Freedman, Julia Forbess, T.G. Falcon, Isabel da Roza and Elena Moreno Cloutier.

Login

Don’t have an account yet?

Register